ArticleFrontiers in immunology2026
The hidden link between iron deficiency and celiac disease: a clinical perspective.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Celiac disease (CD) is an immune-mediated enteropathy triggered by gluten ingestion in genetically predisposed individuals and represents a frequent but underdiagnosed cause of iron deficiency (ID). Screening for CD is recommended in unexplained ID, yet data on its prevalence among patients with absolute ID remain limited. This study aimed to determine the frequency of confirmed CD and Suspected Seronegative CD at Marsh 1 (SSCDM1) and to characterize their clinical, serological, histological, and immunogenetic profiles. Methods: A retrospective study was conducted within the ViaIron cohort including 86 individuals (≥14 years) with absolute ID (ferritin <50 ng/mL), with or without anemia, and no prior CD diagnosis. All underwent serological testing, duodenal biopsy with CD8 Results: Among 86 participants (93% female, median age 41 years), 14% had confirmed CD (Marsh 3) and 39.5% had SSCDM1. Only one-third of confirmed cases were seropositive, and 77% were asymptomatic. SSCDM1 patients closely resembled overt CD, showing low ferritin, hepcidin, and IgA levels but normal inflammatory markers, suggesting a shared malabsorption-driven, non-inflammatory mechanism of iron depletion. Autoimmune comorbidities, particularly autoimmune thyroiditis, and permissive HLA-DQ2/DQ8 haplotypes were highly frequent in both groups. Discussion: Nearly half of participants exhibited either overt or seronegative CD, revealing a continuum between both conditions. These findings highlight a frequently under-recognized, seronegative, immune-mediated duodenal injury consistent with possible gluten-sensitive enteropathy, which may escape detection by standard serological screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.